2024-09-18 - Analysis Report
## REGN Stock Analysis Report

**Company Overview:** Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company focused on the development and commercialization of life-transforming medicines for serious diseases.

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return:** 152.52%
* **S&P 500 (VOO) Cumulative Return:** 89.02%
* **Return Gap:** 63.5%
* **Relative Strength:** 89.94% 

REGN has significantly outperformed the S&P 500, with a 63.5% higher cumulative return. This indicates a strong historical performance relative to the broader market.

**2. Recent Price Movements:**

* **Closing Price:** $1153.08
* **5-day Moving Average:** $1149.74
* **20-day Moving Average:** $1172.45
* **60-day Moving Average:** $1111.65

REGN's price is currently slightly below its 5-day moving average, indicating potential short-term weakness. The stock is also below its 20-day moving average, suggesting a possible downtrend in the near term. However, it is above its 60-day moving average, indicating a longer-term uptrend.

**3. Technical Indicators:**

* **RSI:** 36.1
* **PPO:** -0.56
* **Delta_Previous_Relative_Divergence:** -10.06 (Short-term Downward Trend)
* **Expected Return:** 7.61% 

The RSI suggests that REGN is in oversold territory, indicating potential for a bounce back. However, the negative PPO value and the recent downward trend in relative divergence suggest that the stock might be experiencing weakness in the short term. The expected return of 7.61% indicates a potential for long-term growth.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | $3.55B |
| 2024-05-02 | 6.7 | $3.15B |
| 2023-11-02 | 9.48 | $3.36B |
| 2023-08-03 | 9.05 | $3.16B |
| 2024-08-01 | 9.05 | $3.16B |

REGN's recent earnings have been consistently strong, exceeding analysts' expectations. The most recent earnings report for Q2 2024 showed a positive EPS of 13.25, beating estimates. This strong performance indicates continued growth in the company's business.

**5. Overall Analysis:**

REGN has shown strong historical performance and outperformed the S&P 500. However, recent technical indicators suggest potential short-term weakness. Despite this, the company's strong earnings performance and future growth potential indicate a positive outlook for the long term.

**Recommendation:** While short-term volatility might be expected, REGN remains a strong investment option for long-term investors due to its robust business model and growth prospects. 
